I-Mab to Release Q3 2024 Financial Results on November 14, 2024

Rhea-AI Summary

I-Mab (NASDAQ: IMAB) announced it will release its Q3 2024 financial results on November 14, 2024, before the US market opens. The company will not hold a conference call for Q3 results but plans to host an investor update call with its full-year 2024 results, where it will discuss its clinical pipeline, corporate strategy, and objectives. Financial results and related information will be available on the company's website.

News Market Reaction – IMAB

-3.60%

-3.60% Session move

In the trading session that priced this news, IMAB declined 3.60%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ROCKVILLE, Md., Oct. 31, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that it plans to release financial results for the third quarter ended September 30, 2024, on Thursday, November 14, 2024, pre-market Eastern Time.

The Company will not host a conference call to discuss its third quarter 2024 financial results. The Company intends to host an investor update call in conjunction with its 2024 full-year financial results to discuss its clinical pipeline, corporate strategy, and objectives. Information about financial results, conference calls, webcasts, and other information is posted on the Company's website.

About I-Mab

I-Mab (NASDAQ: IMAB) is a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer.

I-Mab has established operations in Rockville, Maryland, and Short Hills, New Jersey. For more information, please visit https://www.i-mabbiopharma.com and follow us on LinkedIn and X.

I-Mab Investor & Media Contacts
Tyler Ehler
Senior Director, Investor Relations
IR@imabbio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/i-mab-to-release-q3-2024-financial-results-on-november-14-2024-302292364.html

SOURCE I-Mab Biopharma

FAQ

When will I-Mab (IMAB) release its Q3 2024 financial results?

I-Mab will release its Q3 2024 financial results on Thursday, November 14, 2024, before the US market opens (pre-market Eastern Time).

Will I-Mab (IMAB) host a Q3 2024 earnings call?

No, I-Mab will not host a conference call to discuss Q3 2024 financial results. However, the company plans to host an investor update call with its full-year 2024 results.

What will I-Mab (IMAB) discuss in its upcoming full-year 2024 investor update call?

I-Mab plans to discuss its clinical pipeline, corporate strategy, and objectives during the full-year 2024 investor update call.